Certara, Inc. $CERT Shares Bought by Northern Trust Corp

Key Points

• Northern Trust Corp increased its holdings in Certara, Inc. by 4.5%, owning approximately 0.56% of the company valued at $9,071,000 as of the last SEC filing.
• Certara reported quarterly earnings of $0.07 per share, missing estimates, but revenue of $104.57 million exceeded expectations, marking a 12.1% increase year-over-year.
• Wall Street analysts have mixed ratings on Certara, with a consensus price target of $15.14 and five analysts rating it as a "Buy".

Northern Trust Corp raised its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 4.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 916,299 shares of the company's stock after acquiring an additional 39,289 shares during the quarter. Northern Trust Corp owned approximately 0.56% of Certara worth $9,071,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its stake in Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after acquiring an additional 1,866 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Certara in the first quarter worth approximately $31,000. Wells Fargo & Company MN lifted its position in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares during the last quarter. Associated Banc Corp purchased a new stake in shares of Certara during the 1st quarter worth approximately $101,000. Finally, Portside Wealth Group LLC purchased a new stake in shares of Certara during the 1st quarter worth approximately $104,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Stock Performance

Certara stock traded up $0.67 during midday trading on Thursday, hitting $10.92. 1,992,798 shares of the company's stock were exchanged, compared to its average volume of 1,207,411. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $15.69. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.16 and a current ratio of 2.16. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of 218.44 and a beta of 1.43. The firm's 50 day simple moving average is $10.73 and its 200 day simple moving average is $11.29.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The business had revenue of $104.57 million for the quarter, compared to analysts' expectations of $104.14 million. During the same period in the previous year, the business posted $0.07 earnings per share. The company's revenue for the quarter was up 12.1% on a year-over-year basis. Equities research analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CERT. UBS Group reduced their price objective on shares of Certara from $17.50 to $15.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Zacks Research upgraded shares of Certara from a "strong sell" rating to a "hold" rating in a research report on Friday, September 5th. KeyCorp reduced their price objective on shares of Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Finally, Morgan Stanley began coverage on shares of Certara in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, Certara currently has an average rating of "Moderate Buy" and an average price target of $15.14.

Insider Transactions at Certara

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total transaction of $559,366.08. Following the transaction, the insider directly owned 73,979 shares of the company's stock, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.33% of the company's stock.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.